Sugi Predict

Sugi Predict / Compounds / SCHEMBL952722

SCHEMBL952722

SCHEMBL952722

COC(=O)C1CCCN1Cc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.63
▸ FKBP1A P62942 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ SPHK1 Q9NYA1 1/20 0.54
▸ POLB P06746 1/20 0.54
▸ ADRA1D P25100 1/20 0.53
▸ ADRA1A P35348 1/20 0.53
▸ ADRA1B P35368 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ KDM4E B2RXH2 2/20 0.50
▸ CCR4 P51679 1/20 0.50
▸ ACE P12821 1/20 0.50
▸ CNR2 P34972 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19465330 1.00 LTA4H (0.63) LTA4HFKBP1ANPSR1MEN1KMT2A
SCHEMBL952721 1.00 LTA4H (0.63) LTA4HFKBP1ANPSR1MEN1KMT2A
SCHEMBL6540812 0.96 MEN1 (0.60) LTA4HFKBP1AMEN1KMT2APOLB
SCHEMBL7181767 0.96 MEN1 (0.60) LTA4HFKBP1AMEN1KMT2APOLB
SCHEMBL2768950 0.91 FKBP1A (0.54) LTA4HFKBP1ANPSR1MEN1KMT2A
SCHEMBL27801286 0.86 NPSR1 (0.57) NPSR1MEN1KMT2ASPHK1POLB
SCHEMBL24434971 0.86 ALDH1A1 (0.51) LTA4HFKBP1AMEN1KMT2AADRA1D
SCHEMBL4937902 0.86 MEN1 (0.71) MEN1KMT2ASPHK1POLBALDH1A1
SCHEMBL3143329 0.86 ALDH1A1 (0.52) LTA4HFKBP1ASPHK1ADRA1DADRA1A
SCHEMBL22453467 0.86 LTA4H (0.52) LTA4HFKBP1AADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823159-A Carborane derivative and preparation method and application thereof 郑州原理生物科技有限公司 2025-04-15 — — CN disclosed
US-20230044787-A1 TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) 2023-02-09 — — US disclosed
EP-3970723-A1 AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN Asana BioSciences, LLC (US) 2022-03-23 — — EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 — — EP disclosed
EP-3363437-B1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN ENDO PHARMACEUTICALS SOLUTIONS (US) 2021-07-28 — — EP disclosed
CN-107540599-B Aminoindane compounds and their use to treat pain 阿萨纳生物科技有限责任公司 2021-06-04 — — CN disclosed
US-20210155632-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2021-05-27 — — US disclosed
WO-2019152696-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2019-08-08 — — WO disclosed
EP-3287440-B1 PYRROLIDINE COMPOUND SUMITOMO CHEMICAL CO (JP) 2019-03-27 — — EP disclosed
EP-3363437-A1 AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN Endo Pharmaceuticals Solutions Inc. (US) 2018-08-22 — — EP disclosed
US-8053438-B2 Pyrazine compounds as phosphodiesterase 10 inhibitors AMGEN INC. (US) 2011-11-08 — — US disclosed
EP-2364308-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2011-09-14 — — EP disclosed
US-20110160202-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2011-06-30 — — US disclosed
US-20110160182-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2011-06-30 — — US disclosed
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2011-01-27 — — US disclosed
EP-2238128-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-10-13 — — EP disclosed
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-06-03 — — US disclosed
WO-2010057121-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2010-05-20 — — WO disclosed
CN-101671357-A (S)-Alpha, Alpha-fluorine-containing diaryl-2-pyrrolidine methanol derivative as well as preparation and applications thereof UNIV ZHEJIANG TECHNOLOGY 2010-03-17 — — CN disclosed
WO-2009080226-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFIS-AVENTIS (FR) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160182-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A LTA4H 3344/4885FKBP1A 338/4885NPSR1 1674/4885
US-20100137278-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A LTA4H 3344/4885FKBP1A 338/4885NPSR1 1674/4885
US-20110160202-A1 PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS PDE10A, PDE12, PDE5A LTA4H 3344/4885FKBP1A 338/4885NPSR1 1674/4885
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS P2RY1, P2RY12, P2RY11 LTA4H 697/4885FKBP1A 3636/4885NPSR1 114/4885
US-20230044787-A1 TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF LYPLAL1, LYPLA1, LYPLA2 LTA4H 7/4885FKBP1A 1805/4885NPSR1 2182/4885
US-20210155632-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A LTA4H 2423/4885FKBP1A 570/4885NPSR1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.